L-Dopa for Late-Life Depression

(D3 Trial)

Recruiting at 2 trial locations

Overseen By Carmen Andreescu, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Vanderbilt University Medical Center

Must not be taking: Antipsychotics, Mood stabilizers, Antidepressants

Disqualifiers: Substance abuse, Psychosis, Neurological disorder, Suicidality, others

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 4 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 3

100 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether L-Dopa, commonly used for Parkinson's disease, can improve depression symptoms in older adults by enhancing dopamine function in the brain. Researchers aim to determine if it can aid cognitive and motor issues, such as slow thinking and movement, often seen in late-life depression. Participants may qualify if they are 60 or older and have a diagnosis of depression affecting their thinking speed or mobility. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial does not specify if you must stop taking your current medications, but it does exclude those currently or recently (within the past 2 weeks) treated with antipsychotics or mood stabilizers, or those using antidepressants where stopping is not advisable.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that L-Dopa offers promising safety results for humans, particularly in treating depression symptoms in older adults. One study demonstrated that L-Dopa improved symptoms in 90.3% of patients with new-onset Parkinson's disease, indicating it is generally well-tolerated. Another study found that older adults with depression experienced improved thinking speed and walking ability after just three weeks of L-Dopa treatment. These findings suggest that L-Dopa may enhance mood and mobility without major safety concerns.

While L-Dopa is primarily used for Parkinson's disease, researchers are exploring its potential for treating depression. It is important to note that this trial is in its early stages (Phase 2), so while initial results are promising, further research is needed to confirm its safety and effectiveness. Prospective participants should consult a healthcare provider about the possible risks and benefits before joining a trial. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for late-life depression?

L-Dopa is unique in treating late-life depression because it targets the brain's dopamine system, unlike most antidepressants that focus on serotonin. This different approach could provide relief for individuals who haven't responded to traditional treatments. Researchers are hopeful that L-Dopa's action on dopamine will offer faster and potentially more effective results for older adults struggling with depression.

What evidence suggests that L-Dopa might be an effective treatment for late-life depression?

Studies have shown that L-Dopa can help treat depression symptoms, especially in older adults. Research suggests that as people age, their brain's dopamine function decreases, leading to slower thinking and movement. L-Dopa increases dopamine levels, which can help improve these issues. In a study of patients with newly diagnosed Parkinson's disease, 90.3% of participants experienced improved depressive symptoms with L-Dopa. The trial will evaluate the effects of L-Dopa on late-life depression, with participants receiving either L-Dopa first followed by a placebo, or a placebo first followed by L-Dopa. This suggests that L-Dopa may boost mood and motivation in older adults with depression. ^{1 2 6 7 8}

Who Is on the Research Team?

Warren Taylor, MD,MHSc

Principal Investigator

Vanderbilt University Medical Center

Are You a Good Fit for This Trial?

This trial is for adults aged 60 or older with late-life depression, who have slower mental processing or walking speed. They must be able to consent and follow the study's procedures. Excluded are those at high suicide risk, allergic to L-DOPA, recently on certain psychiatric meds, with mobility issues due to joint/spine problems, major neurological disorders like dementia or Parkinson's, unstable illnesses, substance abuse within a year, or other primary psychiatric conditions.

Inclusion Criteria

Your depression score on the MADRS scale is 15 or higher.

I walk slower than average or think slower than others my age.

I have been diagnosed with a form of depression.

Exclusion Criteria

You have a history of severe mental health conditions like psychosis, mania, or bipolar disorder. However, if your main issue is depression and you have other mental health conditions, you may still be eligible.

History of significant radioactivity exposure (nuclear medicine studies or occupational exposure)

I am currently on or recently stopped taking medication for mental health.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Evaluation

Baseline assessments including PET imaging, MRI, neuropsychological evaluation, and mobility assessments

1-2 weeks

1-2 visits (in-person)

Treatment Phase 1

Participants receive either L-DOPA or placebo for 3 weeks, followed by assessments

3 weeks

Weekly visits (in-person)

Crossover Treatment Phase

Participants switch to the opposite intervention (L-DOPA or placebo) for another 3 weeks, followed by assessments

3 weeks

Weekly visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• L-Dopa
• Placebo

Trial Overview

The study tests whether carbidopa/levodopa (L-DOPA), which enhances dopamine in the brain can improve symptoms of depression by speeding up thinking and movement in older adults. Participants will either receive L-DOPA or a placebo without active ingredients to compare effects.

How Is the Trial Designed?

Group I: L-Dopa First / Placebo Second Experimental Treatment 2 Interventions

STEP 1(3 weeks): Participants initially assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa capsules) at 9am. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa capsules) at 9am and 5pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa capsules) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period before proceeding to Step 2. Step 2 (3 Weeks): Participants will receive matching placebo capsules daily. Participants take placebo capusles once daily during week 1 (9am), twice daily during week 2 (9am, 5pm), and three times daily during week 3 (9am, 1pm, 5pm) over three weeks. Following post-trial assessments, participants then enter a 1-week taper period and study drug is withdrawn.

Group II: Placebo First / L-Dopa Second Placebo Group 2 Interventions

Step 1 (3 Weeks): Participants will receive matching placebo capsules daily. Participants take placebo capsules once daily during week 1 (9am), twice daily during week 2 (9am, 5pm), and three times daily during week 3 (9am, 1pm, 5pm) over three weeks. Following post-trial assessments, participants then enter a 1-week taper period before proceeding to Step 2. Step 2 (3 Weeks): Participants will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa capsules) at 9am. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa capsules) at 9am and 5pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa capsules) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period and study drug will be discontinued.

L-Dopa is already approved in European Union, United States, Canada, Japan for the following indications:

Approved in European Union as Carbidopa/Levodopa for:

• Parkinson's disease
• Restless legs syndrome

Approved in United States as Carbidopa/Levodopa for:

• Parkinson's disease
• Restless legs syndrome
• Neuroleptic malignant syndrome

Approved in Canada as Carbidopa/Levodopa for:

• Parkinson's disease
• Restless legs syndrome

Approved in Japan as Carbidopa/Levodopa for:

• Parkinson's disease

Who Is Running the Clinical Trial?

Vanderbilt University Medical Center

Lead Sponsor

Trials

922

Recruited

939,000+

Rutgers University

Collaborator

Trials

127

Recruited

2,814,000+

University of Pittsburgh

Collaborator

Trials

1,820

Recruited

16,360,000+

University of Pittsburgh Medical Center

Collaborator

Trials

78

Recruited

77,600+

Columbia University

Collaborator

Trials

1,529

Recruited

2,832,000+

Emory University

Collaborator

Trials

1,735

Recruited

2,605,000+

Published Research Related to This Trial

In a 39-week study involving 423 patients with early Parkinson's disease, levodopa/carbidopa/entacapone (LCE) showed a statistically significant improvement in overall symptoms compared to levodopa/carbidopa (LC), with a mean difference of 1.7 points on the Unified Parkinson's Disease Rating Scale (UPDRS).

LCE also demonstrated greater benefits in daily living activities and patient-reported outcomes without increasing the risk of motor complications like dyskinesia, although it was associated with more frequent nausea and diarrhea.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Hauser, RA., Panisset, M., Abbruzzese, G., et al.[2022]

A clinical trial involving 587 patients with early Parkinson's disease compared the effects of L-Dopa monotherapy with a peripheral decarboxylase inhibitor to a combination therapy of L-Dopa and bromocriptine, showing that early combination therapy may help mitigate adverse effects like dyskinesia.

The trial emphasized the importance of monitoring motor performance and adverse events over a 54-month period, indicating that combining dopamine agonists with L-Dopa could enhance treatment outcomes for Parkinson's patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Przuntek, H., Welzel, D., Blümner, E., et al.[2019]

In a study involving 29 patients with Parkinson's disease, Sinemet-CR demonstrated a high effectiveness rate of 80%, particularly improving symptoms like rigidity, hypokinesia, and tremor over a treatment duration of 3 months.

The treatment was found to be safe, with only 6 cases reporting negative side effects, supporting its recommendation for broader use in managing Parkinson's disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[The use of the Sinemet-CR preparation in treating Parkinson's disease]. Artem'ev, DV., Damulin, IV., Iakhno, NN.[2016]

In a study of 18 patients with Parkinson's disease, Sinemet (L-dopa and carbidopa) was found to provide the same therapeutic benefits as L-dopa alone but at lower doses and with fewer side effects.

Both Sinemet and L-dopa were most effective in reducing bradykinesia and muscular rigidity, while their impact on tremors was less pronounced.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Comparison between results achieved by administering L-dopa and Sinemet in parkinsonism in the light of our records]. Szulc-Kuberska, J., Niewodniczy, A., Poźniak-Patewics, E., et al.[2019]

Levodopa/carbidopa intestinal gel infusion is a viable long-term treatment option for advanced Parkinson's disease, with a median treatment duration of 3.4 years and some patients remaining on treatment for nearly 8 years.

The most common reason for discontinuation of the treatment was device-related problems, highlighting the importance of device reliability in the long-term management of Parkinson's disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Nyholm, D., Klangemo, K., Johansson, A.[2015]

In a three-year open-label trial with 18 patients, Sinemet CR (carbidopa/levodopa) showed no significant change in daily dosing frequency, indicating stable long-term management of Parkinson's symptoms.

While patients experienced stable 'on' time, there was an increase in 'on with dyskinesias' over the study period, but no serious side effects or adverse laboratory results were linked to the medication.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations. Hutton, JT., Morris, JL.[2019]

Sinemet, a combination of levodopa and carbidopa, has significantly improved the treatment of parkinsonism by reducing side effects like nausea and arrhythmias, while providing effective relief from rigidity and akinesia, especially in the first three years of treatment.

Despite its benefits, Sinemet can lead to complications such as involuntary movements and psychosis, and it is not a cure for parkinsonism; ongoing research into other drugs and neurotransmitter mechanisms offers hope for future treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Sinemet and the treatment of Parkinsonism. Boshes, B.[2019]

In a study of 40 patients treated with Sinemet (L-carbidopa/L-dopa) for up to two years, about two-thirds experienced good to very good improvements in their Parkinson's disease symptoms.

While side effects like dyskinesia and gastrointestinal issues were noted, they were generally manageable and did not require stopping treatment, making Sinemet a viable option for managing Parkinson's disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study]. Hayek, J.[2013]

In an open-label study involving eight patients with Parkinson's disease, selegiline was found to have several side effects, particularly in elderly patients.

Urinary retention occurred in two patients, highlighting the need for caution when prescribing selegiline as an adjunct treatment for Parkinson's disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Side effects of selegiline (Eldepryl). Waters, CH.[2019]

In a study of 38 patients with Parkinson's syndrome, Madopar (a combination of L-dopa and a peripheral decarboxylase inhibitor) showed clinical improvement in about 67% of patients, particularly in reducing bradykinesia and rigidity, although tremor improvement was minimal.

Side effects were observed in approximately 40% of patients, but they were generally mild and temporary, with the main contraindications being psychotic disturbances; Madopar also enhanced the effectiveness of long-term L-dopa treatment in patients receiving it as an adjunct therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Treatment of parkinsonism with L-dopa and peripheral decarboxylase inhibitor]. Dowzenko, A., Buksowicz, C., Kuran, W.[2015]

In a 16-week study involving 20 patients with Parkinson's disease, both Madopa and Sinemet significantly reduced nausea and vomiting caused by levodopa therapy, with 70% of patients showing improvement in their disability compared to baseline.

While the overall group results showed no significant difference in efficacy between Madopa and Sinemet, individual responses indicated that most patients had a preference for one treatment over the other, suggesting personalized treatment may be beneficial.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease. Diamond, SG., Markham, CH., Treciokas, LJ.[2019]

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT03761030

NCT03761030 | L-DOPA vs. Placebo for Depression and ...

Available evidence suggests that declining functionality in the brain's dopamine system contributes to age-related cognitive and motor slowing. The central ...

2.

sciencedirect.com

sciencedirect.com/science/article/pii/S0165178122006011

The effectiveness of off-label dopamine stimulating agents ...

We hypothesize that dopamine stimulating agents as a group are overall effective in reducing depressive symptoms, particularly later in life. 2. Methods. The ...

3.

clinicaltrials.gov

clinicaltrials.gov/study/NCT04650217

Levodopa and Exercise for Older Adults With Depression ...

Below, we evaluate whether complementary effects on effortful behavior may be achievable via L-DOPA increasing subjective value and Exercise reducing effort ...

4.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC3010522/

Depression in Parkinson's disease: Symptom Improvement ...

Treatment response was associated with significant improvements in the core mood, anxiety, insomnia, and somatic symptoms seen in dPD. Residual symptoms, like ...

5.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC6641997/

Effects of L-DOPA Monotherapy on Psychomotor Speed and ...

L-DOPA has been reported to relieve depressive symptoms in new onset PD, improving symptoms in 90.3% of patients (N=31) and resulting in a mean ...

6.

clinicaltrials.gov

clinicaltrials.gov/study/NCT02744391

A Study of L-DOPA for Depression and Slowing in Older ...

Available evidence suggests that declining functionality in the brain's dopamine system contributes to age-related cognitive and motor slowing. The central ...

7.

jwatch.org

jwatch.org/na48997/2019/05/03/late-life-depression-levodopa-improves-psychomotor-speed

In Late-Life Depression, Levodopa Improves Psychomotor ...

In a 3-week, open-label study of older depressed patients without Parkinson disease, processing speed and gait improved with levodopa.

8.

sciencedirect.com

sciencedirect.com/science/article/pii/S0889159124007554

Sustained effects of repeated levodopa (L-DOPA) ...

L-DOPA improved effort-based motivation, with preliminary effects on anhedonia and depression severity. 3.2.1. Primary behavioral outcome, objective-motivation.